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Hypertension affects nearly 20% of the population in Western countries and strongly increases 
the risk for cardiovascular diseases. In the pathogenesis of hypertension, the vasoactive peptide 
of the renin-angiotensin system, angiotensin II and its G protein–coupled receptors (GPCRs), 
play a crucial role by eliciting reactive oxygen species (ROS) and mediating vessel contractility. 
Here we show that mice lacking the GPCR-activated phosphoinositide 3-kinase (PI3K)
 
 
 
 are 
protected from hypertension that is induced by administration of angiotensin II in vivo. PI3K
 
 
 
 
was found to play a role in angiotensin II–evoked smooth muscle contraction in two crucial, 
distinct signaling pathways. In response to angiotensin II, PI3K
 
 
 
 was required for the activation 
of Rac and the subsequent triggering of ROS production. Conversely, PI3K
 
 
 
 was necessary to 
activate protein kinase B/Akt, which, in turn, enhanced L-type Ca
 
2
 
 
 
 channel–mediated 
extracellular Ca
 
2
 
 
 
 entry. These data indicate that PI3K
 
 
 
 is a key transducer of the intracellular 
signals that are evoked by angiotensin II and suggest that blocking PI3K
 
 
 
 function might be 
exploited to improve therapeutic intervention on hypertension.
 
Angiotensin II is the primary effector peptide
of the renin-angiotensin system and acts as a
hormonal and local factor. It plays a key role in
blood pressure homeostasis; high plasma levels
of the peptide are a main trait of renovascular
hypertension. In addition, angiotensin II over-
activity has been involved in other widely dif-
fused cardiovascular diseases, such as athero-
sclerosis and congestive heart failure.
The effects of angiotensin II are exerted on
several target organs; however, especially the
vascular action explains its impact on blood
pressure. Angiotensin II increases vascular tone
by activating calcium-flux, oxidative stress,
and cell growth in vascular smooth muscle
and, concomitantly, by promoting an inflam-
matory reaction in the vessel wall.
Several pharmacological interventions have
been developed to attenuate angiotensin II
vascular effects. In particular, inhibition of angio-
tensin II synthesis and, subsequently, blocking
of its high affinity subtype-1 (AT
 
1
 
) have allowed
the targeting of angiotensin II-dependent neg-
ative effects.
Recent evidence suggests that the vasculo-
toxic effects of angiotensin II can be mediated
via PI3K signaling pathways (1). PI3Ks are a
family of lipid and protein kinases that are re-
sponsible for the phosphorylation of PtdIns at
the position D3 of the inositol ring. These
molecules act as secondary messengers and in-
fluence a variety of cellular responses, including
proliferation, survival, and cytoskeletal remod-
eling (2). In vivo, PI3Ks of the class I subfamily
produce PtdIns(3,4,5)P
 
3
 
 that serves as a dock-
ing site for the pleckstrin homology domain
that is present in numerous proteins that act as
PI3K downstream effectors. Class I PI3Ks are
divided in two subgroups depending on their
biochemical properties. The class IA group
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consists of PI3Ks that—with the exception of PI3K
 
 
 
 that
also can respond to GPCRs—are activated mainly by ty-
rosine kinase receptors (3). Conversely, the unique member
of class IB, PI3K
 
 
 
 (p110
 
 
 
), is activated exclusively by
GPCRs; it binds directly to the 
 
  
 
 subunits of heterotri-
meric G proteins (4) but its activity also can be modulated by
interaction with an adaptor protein, p101 (5). Deletion of
the 
 
PI3K
 
 
 
 gene in mice is compatible with life and causes
a protection from leukocyte recruitment by inflammatory
stimuli (6, 7). A growing set of evidence indicates that
PI3K
 
 
 
 also is expressed in the cardiovascular system where it
negatively controls cardiomyocyte contractility (8–10).
The specific PI3K isoform that is involved in angiotensin
II signaling is still controversial. Using pharmacological in-
hibitors that block PI3K function without distinguishing be-
tween isoforms, it has been found that, in vascular smooth
muscle cells, angiotensin II requires a PI3K activity to stimu-
late calcium channels and induce the calcium influx that
governs the vascular contractile response (11). Although in
porcine coronary artery smooth muscles, tyrosine phosphor-
ylation and class IA PI3Ks may be involved (12), in rat portal
vein myocytes, the free 
 
 
 
1
 
 
 
3
 
 dimers that are generated by
the activation of the G
 
13
 
-coupled AT
 
1A
 
 receptor directly
stimulate PI3K activity; this indicates a crucial role for the
class IB enzyme, PI3K
 
 
 
 (13). Recent evidence indicates that
PI3K
 
 
 
 and PI3K
 
 
 
, but not PI3K
 
 
 
, are expressed by myo-
cytes freshly isolated from rat portal veins (14). Although
classes IA and B PI3K isoforms are present in rat portal vein
myocytes, injection of antibodies that recognize different
PI3K isoforms into these cells indicates that the angiotensin
II-dependent activation of L-type Ca
 
2
 
 
 
 current is inhibited
by blocking PI3K
 
 
 
 but not PI3K
 
 
 
; this suggests a crucial
role for PI3K
 
 
 
 in angiotensin II signal transduction (15).
Despite the finding that smooth muscle cells require PI3K
 
 
 
for the angiotensin II–mediated intracellular Ca
 
2
 
 
 
 concentra-
tion increase, in vivo studies that address the role of PI3K
 
 
 
 in
vascular responses to angiotensin II are missing. We examined
the vascular responses to angiotensin II stimulation in mice
lacking PI3K
 
 
 
 and found that PI3K
 
 
 
 
 
/
 
 
 
 vessels show reduced
contractile responses to angiotensin II, a markedly decreased
angiotensin II–mediated ROS production, and intracellular
Ca
 
2
 
 
 
 mobilization. As a consequence of these effects, mice
lacking PI3K
 
 
 
 are protected strongly from the hypertension
that is induced by administration of angiotensin II in vivo.
 
RESULTS
PI3K
 
 
 
 
 
/
 
 
 
 mice are protected from angiotensin II–induced 
hypertension
 
To investigate in an in vivo model whether PI3K
 
 
 
, the pro-
totype GPCR-activated PI3K, plays a role in angiotensin II–
Figure 1. The lack of PI3K  protects in vivo from the hypertensive 
response evoked by angiotensin II. Daily systolic and diastolic blood 
pressure (A) and heart rate (B) profiles, recorded by radiotelemetry, in 
wild-type (empty circles; n   8) and PI3K  /  (filled circles; n   8) mice 
in response to 21 d of chronic infusion of angiotensin II. Angiotensin II is 
able to exert a significant hypertensive effect only in wild-type mice 
(PI3K  /  vs. wild-type controls *P   0.03, two-way ANOVA analysis and 
Bonferroni post hoc test). Heart rate increase (10% over basal) is compa-
rable in both mouse strains (P   0.90). In contrast, the lack of PI3K  does 
not alter blood pressure (C) or heart rate (D) in response to phenylephrine. 
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induced hypertension, wild-type and PI3K
 
 
 
 
 
/
 
 
 
 mice were
challenged chronically with angiotensin II. As shown in Fig.
1 A, angiotensin II treatment induced a progressive increase
in systolic and diastolic blood pressure in wild-type mice. In
contrast, the hypertensive response seemed to be attenuated
significantly in PI3K
 
 
 
 
 
/
 
 
 
 animals; at the end of angiotensin
II treatment, blood pressure increase of mutant mice was
 
 
 
30% of that detected in wild-type controls (systolic blood
pressure increase 
 
 
 
 9 
 
 
 
 4 mm Hg vs. 32 
 
 
 
 5 mm Hg; % in-
crease over basal diastolic blood pressure was 11% 
 
 
 
 4% vs.
29% 
 
 
 
 4%; 
 
n
 
 
 
 
 
 8). Nevertheless, chronic angiotensin II
caused comparable changes of heart rate in both genotypes
(Fig. 1 B). Echocardiographic analysis showed no signs of di-
lated cardiomyopathy or depressed systolic function in either
mice strain (unpublished data); this excludes an involvement
of cardiac effects on blood pressure. Infusion of phenyleph-
rine influenced blood pressure (Fig. 1 C) and heart rate (Fig.
1 D) to a similar extent in both mouse strains.
 
The lack of PI3K
 
 
 
 protects from angiotensin II–mediated 
vascular damage
 
To test whether the lack of PI3K
 
 
 
 could protect vessels from
the toxic effects of chronic angiotensin II stimulation, struc-
tural remodeling of the mesenteric wall and coincident in-
flammatory response were analyzed after 21 d of angiotensin
II infusion. In wild-type mice, morphometric analysis of mes-
enteric arteries revealed a significant increase in MCSA and
media/lumen ratio, but not in lumen diameter. This mor-
phological pattern, typical of hypertrophic vascular remodel-
ing, was blunted significantly in PI3K
 
 
 
 
 
/
 
 
 
 animals (Fig. 2,
A–C). Conversely, chronic infusion of phenylephrine in-
duced eutrophic remodeling, with increased media/lumen
ratio, but not MCSA (16), that was equally evident in mutant
and control samples. The possible involvement of different
recruitment of inflammatory cells in the vessel wall was eval-
uated next. Immunohistochemistry that used neutrophil-,
macrophage-, and lymphocyte-specific markers showed
equally low infiltrates in both genotypes (unpublished data).
Nonetheless, PI3K
 
 
 
-deficient vessels expressed lower levels
of vascular cell adhesion molecule-1, an adhesion receptor in-
duced by angiotensin II, than wild-type controls (Fig. 2 D).
 
PI3K
 
 
 
 
 
/
 
 
 
 mice show a blunted angiotensin II–dependent 
vasoconstriction
 
Angiotensin II can increase blood pressure after chronic
treatment and in response to acute stimulation. PI3K
 
 
 
 
 
/
 
 
 
mice showed a reduced blood pressure increase in response
to acute angiotensin II administration (Fig. 3 A); this indi-
cates a specific involvement of PI3K
 
 
 
 in the acute and
chronic hypertensive effects of angiotensin II. As a conse-
quence, the effects of the lack of PI3K
 
 
 
 on angiotensin II–
mediated vascular reactivity were studied next. In wild-type
mesenteric arteries, angiotensin II induced a significantly
blunted vasoconstriction in PI3K
 
 -deficient vessels (Fig. 3
B). This effect also was observed in endothelium denuded
vessels (unpublished data), which indicates that the lack of
PI3K  affected smooth muscle cell–dependent responses.
The maximal difference was obtained at 1  M angiotensin II
where contractility of PI3K  /  vessels was only 27%   5%
of that of wild-type controls. The use of wortmannin re-
duced angiotensin II vasoconstriction in wild-type samples,
and leveled vascular reaction to that observed in PI3K  / 
vessels (Fig. 3 B). To prove further a specific involvement of
PI3K  enzymatic activity in angiotensin II–mediated vascu-
lar contractility, vasoconstriction that was induced by angio-
tensin II was tested in vessels that were derived from
PI3K KD/KD mice that expressed a catalytically inactive
PI3K  (10). PI3K KD/KD mice showed an impaired angio-
tensin II–evoked increase in blood pressure (% mean arterial
pressure increase: 25   2% vs. 4   1%, in wild-type and
PI3K KD/KD mice, respectively; P   0.01, one-way ANOVA;
n   4 for both genotypes) and vasoconstriction (max vaso-
constriction: 620   50 mg vs. 220   35 mg in wild-type
and PI3K KD/KD vessels, respectively; P   0.01; n   4 for
both genotypes). This demonstrated that the enzymatic ac-
tivity of PI3K  is required for angiotensin II–mediated vas-
cular effects.
Furthermore, although pharmacological inhibition of
AT2 receptors did not affect the differences that were ob-
served between the two genotypes, blockade of AT1 recep-
tors abolished vasoconstriction to angiotensin II in PI3K  / 
and PI3K  /  mice (unpublished data). Other vasoactive
Figure 2. The lack of PI3K  protects from angiotensin II–induced 
vascular remodeling and activation. (A) Measurement of the media/lumen 
ratio (M/L) of aortas from wild-type (white bars) and PI3K  /  (black bars) 
mice before (S) and after 3 wk of chronic angiotensin II (Ang II) or phenyl-
ephrine (PE) infusion; n   5 for both genotypes; *P   0.05 by ANOVA. 
(B) Measurement of the MCSA; n   5; *P   0.05 by ANOVA. (C) Measure-
ment of the internal diameter (ID); n   5; P   0.90 by ANOVA. (D) Western 
blot analysis of vascular cell adhesion molecule-1 (VCAM-1) expression in 
aortas of wild-type (WT) and PI3K -deficient mice after chronic angio-
tensin II. Data are representative of three independent experiments.PI3K  VASCULAR EFFECTS | Vecchione et al. 1220
agonists, such as acetylcholine and phenylephrine, evoked a
similar response in the two mouse strains (Fig. 3 C and D)
that was unaffected by pretreatment with wortmannin (not
depicted). Altogether, these results indicate that the catalytic
activity of PI3K  plays a specific key role in the AT1-medi-
ated signal transduction that leads to vascular contraction.
Impaired angiotensin II-dependent Akt phosphorylation 
in PI3K -deficient aortas
To test a possible involvement of PI3K  in angiotensin II–
mediated signal transduction and in the vascular responses
that lead to hypertension, primary smooth muscle cells were
isolated from aortas of wild-type and PI3K  null mice. The
cells were stained positive for smooth muscle actin and, when
derived from wild-type animals, presented the mRNA for
PI3K  (Fig. 4 A). Similarly, only wild-type cells showed the
expression of the PI3K  protein, albeit at very low levels
(Fig. 4 B, top). In PI3K  /  samples, no changes in expres-
sion of other PI3Ks (e.g., PI3K ) were detected in mutant
samples (Fig. 4 B, bottom). Because PI3K  could play a role
in GPCR-mediated signaling, cultures were expanded for no
more than five passages and cells were stimulated with angio-
tensin II. In apparent contrast to a putative role of PI3K  in
angiotensin II signaling, analysis of the PI3K-dependent
phosphorylation of protein kinase B (PKB)/Akt at Ser473 did
not show any difference between wild-type and mutant cells
(Fig. 4 C). However, in aortic smooth muscle cells (ASMCs)
of both genotypes, the angiotensin II activation of PKB/Akt
was blocked by the EGFR kinase blocker, AG1478 (Fig. 4
C). These results are in agreement with the previous finding
that in vascular smooth muscle cells, angiotensin II–mediated
signaling triggers EGFR transactivation (17), and thus, by-
passes PI3K  function by an EGFR-dependent activation of
class IA PI3Ks.
Figure 3. PI3K  modulates angiotensin II-dependent vasoconstriction. 
(A) Acute effect of angiotensin II on mean arterial pressure in wild-type 
(white bars; n   4) and PI3K  /  (black bars; n   4; wild-type vs. PI3K  /  
P   0.01 by ANOVA). Basal blood pressure was identical in the two geno-
types (see Figure 1). (B) angiotensin II-dependent vasoconstriction in 
PI3K  /  (empty triangles, continuous line; n   12) and wild-type (WT) 
vessels (empty squares, dotted line; n   12; *P   0.01, two-way ANOVA 
and Bonferroni post hoc test). In the presence of wortmannin (Wort, filled 
symbols), angiotensin II–mediated vasoconstriction is reduced only in 
wild-type arteries (filled squares, dotted line, n   12; wild-type samples 
vs. wild-type samples in the presence of wortmannin *P   0.01). (C, D) Vascu-
lar relaxation to acetylcholine or contraction to phenylephrine are not 
affected by the absence of PI3K . Relaxation to acetylcholine is expressed 
as percentage of the tension attained with an initial stimulation with 
1  M phenylephrine.
Figure 4. PI3K  expression in murine smooth muscle cells. (A) RT-PCR 
analysis of PI3K  expression in wild-type and PI3K  /  primary ASMCs. 
PI3K  expression can be detected only in wild-type samples. The leftmost 
Actin lane corresponds to a control amplification of the PI3K  /  sample. 
The absence of CD18 expression excludes a possible contribution of con-
taminating leukocytes to the PI3K  signal. C, control amplification with 
water only. M, molecular weight markers. (B) Detection of PI3K  (p110 ) 
expression by immunoprecipitation of 1 mg of proteins extracted from 
primary wild-type and PI3K  /  ASMCs. Detection of PI3K  (p110 ) 
expression by Western blot analysis of supernatants. (C) Angiotensin II-
induced PKB/Akt phosphorylation is mediated by EGFR transactivation in 
wild-type ( / ) and PI3K  /  ( / ) in vitro cultured ASMCs. Encircled 
“P” denotes phosphorylated. Cells were stimulated for 5 min with saline (Co) 
angiotensin II. EGFR transactivation was inhibited by AG1478 (250 nmol/L) 
before angiotensin II stimulation. Panels are representative of five inde-
pendent experiments.JEM VOL. 201, April 18, 2005 1221
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To test whether PI3K  function was required for angio-
tensin II–dependent signal transduction in vivo, studies were
conducted on intact aortas. First, PI3K  expression was in-
vestigated by immunohistochemistry and the smooth muscle
cell layer was stained positive for the enzyme (Fig. 5 A).
Next, expression was validated in aortic tissue preparations
that expressed PI3K  and smooth muscle actin but little
CD18; this indicated a relatively small contamination of leu-
kocytes and a major presence of smooth muscle cells (Fig. 5
B). After i.p. stimulation with different doses of angiotensin
II, only wild-type samples showed PKB/Akt phosphoryla-
tion (1.8   0.6 and 3.5   0.3 fold induction vs. unstimu-
lated control for 0.1 and 10  M angiotensin II, respectively;
n    7; P   0.05 and P   0.01, respectively; one-way
ANOVA). This process was impaired strongly in PI3K -
deficient aortas (1   0.1 and 1.3   0.3 fold induction over the
unstimulated control for 0.1 and 10  M angiotensin II, re-
spectively; n   7, not significant). i.p. administration of 0.5
mg/kg AG1478 (suspended in 0.2% carboxymethylcellulose
and sonicated), known to abrogate EGFR activation in vivo
(18), in wild-type mice did not affect PKB/Akt activation;
this indicates that, in vivo, EGFR transactivation is not in-
volved (unpublished data). To prove further the specificity
of this defect, PKB/Akt activation was tested after stimula-
tion with insulin, an agonist that is known to signal through
PI3K isoforms different from PI3K . As shown in Fig. 5 B,
tissue samples from mutant and control mice showed an
identical ability to phosphorylate PKB/Akt. As expected
from a reduced PKB/Akt activation, phosphorylation of gly-
cogen synthase kinase (GSK)3- , a known substrate of
PKB/Akt, was decreased in PI3K -deficient aortas after an-
giotensin II, but not insulin, stimulation. Conversely, no dif-
ference in extracellular signal–regulated kinase (ERK)1/2
activation was detected in mice of the two genotypes.
In wild-type vessels, PKB/Akt phosphorylation after an-
giotensin II stimulation was reduced by a pretreatment with
PTX to the level that was detected in mutant samples (Fig. 5
C). In contrast, no further decrease in PKB/Akt phosphory-
lation could be detected in PTX-treated mutant vessels; this
indicates the involvement of a PTX-sensitive G i-coupled
angiotensin II receptor in PI3K  activation.
PI3K  /  mice are protected from angiotensin II–evoked 
vascular ROS generation
In hypertension, the increase of vascular ROS contributes to
endothelial dysfunction and vessel contraction. Because an-
giotensin II induces ROS production in vascular smooth
muscle cells, the involvement of PI3K  in this process was
evaluated next. To test the effects of angiotensin II–mediated
ROS production, vascular contractility was measured after
the combined administration of angiotensin II and tiron, a
potent ROS scavenger. As expected, in wild-type vessels,
tiron significantly reduced the angiotensin II–dependent en-
hancement of vascular wall tension. In contrast, in mutant
vessels, the addition of tiron did not modify further the
Figure 5. Aortic smooth muscle PI3K  modulates angiotensin II–
dependent activation of PKB/Akt. (A) Immunohistochemical localiza-
tion of PI3K  expression in a section of a mouse aorta. Note brown 
reactivity only in the smooth muscle cell layer of wild-type (PI3K  / ). 
Bars, 100  m. (B) PI3K  expression in aortic tissue extracts. Phosphory-
lation of PKB/Akt and GSK3-  shows a concentration-dependent in-
crease in angiotensin II–stimulated wild-type aortas, which is impaired 
in PI3K -deficient vessels. Conversely, angiotensin II-mediated ERK1 
and 2 phosphorylation are not affected. Stimulation of PKB/Akt and 
GSK3-  phosphorylation is identical in aortas of the two genotypes 
treated with insulin. Equal loading is evidenced by the detection of the 
total nonphosphorylated proteins. Panels are representative of three 
independent experiments. PBS, saline control; SM, smooth muscle. 
(C) angiotensin II–dependent PKB/Akt is mediated by a G i-coupled 
receptor. angiotensin II-dependent phosphorylation of PKB/Akt is lost 
equally in PTX-treated and PI3K -deficient aortas. Panels are represen-
tative of three independent experiments.PI3K  VASCULAR EFFECTS | Vecchione et al. 1222
blunted response to angiotensin II; this suggests that angio-
tensin II-evoked ROS generation requires the activation of
PI3K  (Fig. 6 A). To prove further that PI3K  was involved
in the angiotensin II–mediated ROS production, the gener-
ation of ROS was measured directly in wild-type and mu-
tant vessels after angiotensin II stimulation. The levels of
ROS production in tissues of the two genotypes were com-
parable in basal conditions (Fig. 6 B). After administration of
angiotensin II, wild-type vessels responded with a significant
increase of ROS generation over the basal level (370%  
70% over control, P   0.01); this effect was blocked by pre-
incubation with wortmannin (Fig. 6 B). In contrast, stimu-
lated PI3K -deficient aortas showed a response that was re-
duced by 70% over that of similarly treated wild-type
samples (P   0.05); wortmannin did not affect this response
further. PI3K KD/KD mice showed a similarly impaired re-
sponse (unpublished data); this confirms that the catalytic ac-
tivity of PI3K  is a key event that is necessary for the angio-
tensin II–dependent generation of ROS. This effect was
mediated by AT1 receptors because it was inhibited by can-
desartan, but not by PD123319 (unpublished data). Angio-
tensin II-mediated ROS production was inhibited signifi-
cantly by pretreatment with PTX; this further suggested an
involvement of a G i-coupled angiotensin II receptor in ves-
sel (Fig. 6 B). In addition, vascular ROS production that was
evoked by phenylephrine, an agonist of a G q-coupled re-
ceptor, was very weak and seemed to be similar in both
mouse strains (Fig. 6 B).
The signaling pathway that links PI3Ks to ROS produc-
tion involves the PI3K-dependent activation of Rac, which,
in turn, triggers nicotinamide adenine dinucleotide (phos-
phate) (NAD[P]H)-oxidase–dependent ROS generation (17,
19). Although Rac activation increased in stimulated wild-
type samples, this effect was reduced markedly in mutant
vessels (Fig. 6 C). These data suggest that the lack of PI3K 
impairs ROS production because of a reduced activation of
Rac in response to angiotensin II.
In the vasculature, superoxide can react with other free
radicals, such as nitric oxide, and generate peroxynitrites that
lead to nitrotyrosine production. In wild-type samples, tyro-
sine nitration was undetectable in basal conditions but be-
came apparent after stimulation with angiotensin II (Fig. 6 D,
left). In contrast, the level of nitrotyrosines in aortas that were
derived from PI3K  /  mice was undetectable in basal con-
ditions and after angiotensin II stimulation (Fig. 6 D, right).
PI3K  is required for angiotensin II–mediated extracellular 
Ca2  entry through activation of PKB/Akt
Although in wild-type vessels, contractility in response to
angiotensin II was reduced by tiron, the impact of the anti-
oxidant was smaller than that caused by the lack of PI3K 
(Fig. 6 A). This observation suggested that in the absence of
Figure 6. PI3K  is involved in the vascular ROS production induced 
by angiotensin II. (A) Tiron reduced angiotensin II–mediated vasocon-
striction of only wild-type mesenteric arteries (n   6; *P   0.01, two-way 
ANOVA and Bonferroni post hoc test). (B) Measurement of ROS by chemi-
luminescence before and after stimulation of vessels from wild-type (n   4) 
and PI3K  /  mice (n   4) with angiotensin II (1  M) alone and after PTX 
(250 ng/ml), wortmannin (100 nM), or phenylephrine (1  M). Angiotensin II–
evoked ROS production is blunted significantly in PI3K  /  mice (§P   0.01 
basal vs. stimulated, *P   0.01 wild-type vs. PI3K  /  stimulated vessels, 
one-way ANOVA). Similarly, PTX treatment reduces the ROS production 
only in the wild-type samples (‡P   0.01 stimulated vs. PTX-treated stim-
ulated wild-type vessels). (C) Representative immunoblot of GTP-bound 
Rac. At 2 min after angiotensin II stimulation, Rac activation is reduced 
markedly in PI3K  /  samples. Mutant vessels, however, show normal 
Rac activation after treatment with the unspecific Rac activator, GTP S. 
(D) Immunohistochemical detection of nitrotyrosines in aortas from wild-
type and PI3K  /  mice stimulated with 1  M angiotensin II. Angiotensin II-
induced nitration of vascular proteins is blunted in PI3K  /  mice. Panels 
are representative of three independent experiments.JEM VOL. 201, April 18, 2005 1223
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PI3K , the impaired angiotensin II–mediated vasoconstric-
tion was due not only to reduced ROS production. During
vessel contraction, a crucial role is played by the increase of
intracellular Ca2 , which stimulates the contractile machin-
ery. To test whether the reduced contractile response to an-
giotensin II in PI3K  /  vessels was due to a defective in-
duction of intracellular calcium increase, the ability of
angiotensin II to enhance [Ca2 ]i was evaluated in wild-type
and mutant mesenteric artery preparations. In resting condi-
tions, vessels of wild-type and mutant mice showed similarly
low fluorescence levels (Fig. 7 A). The addition of angio-
tensin II caused a time-dependent increase in fluorescence
intensity with a maximal peak at 70 s after agonist exposure
(Fig. 7 A). However, the peak fluorescence that was de-
tected in PI3K -deficient vessels was 73% weaker than that
measured in wild-type controls (Fig. 7 B, n   7). In contrast,
phenylephrine elicited a comparable fluorescence response
in wild-type and mutant samples (Fig. 7 B).
To define better the role of PI3K  in angiotensin II-
evoked Ca2  mobilization, a concentration response curve
for angiotensin II was determined at 70 s after stimulation
and [Ca2 ]i was quantitated from the fluorescence measure-
ments (Fig. 7 C). Vessels of both genotypes showed a maxi-
mal Ca2  mobilization with 0.1  M angiotensin II; how-
ever, the [Ca2 ]i induced in mutant samples always was
weaker than in wild-type controls. In particular, the maxi-
mal response of mutant samples was reduced by 60% (P  
0.05, Bonferroni post hoc test); this confirms further that the
lack of PI3K  impairs vascular calcium mobilization in re-
sponse to angiotensin II. Because this difference may be due
to abnormal intracellular calcium release or extracellular cal-
cium entry, Ca2  flux was analyzed after depletion of intra-
cellular Ca2  stores by preincubation with thapsigargin, a
specific inhibitor of Ca2 -ATPase pumps (20). After this
treatment, the residual angiotensin II–induced increase in
[Ca2 ]i (Fig. 7 D) and vasoconstriction (unpublished data)
remained higher in wild-type samples than in PI3K  /  ves-
sels; this excludes an involvement of PI3K  in angiotensin
II–induced intracellular Ca2  fluxes. Next, calcium entry
was analyzed by incubation of vessels in a Ca2 -free medium
that contained 0.1 mM EGTA, or in the presence of the
L-type Ca2  channel antagonist, nifedipine (1  M). Consis-
tent with angiotensin II causing Ca2  entry mainly through
L-type channels, both treatments blocked the angiotensin II–
mediated Ca2  influx in wild-type and PI3K  /  samples
(Fig. 7 D). In addition, inhibition of T-type Ca2  channels
Figure 7. The PI3K /Akt pathway is involved in the extracellular 
calcium entry induced by angiotensin II. (A) Time-dependent changes 
in vascular Ca2  release in the vessels expressed in arbitrary units. (B) Average 
of peak-to-basal change in Fluo4-AM fluorescence intensity in mesenteric 
arteries from wild-type (n   7) and PI3K  /  (n   8) mice in response to 
angiotensin II and phenylephrine. Angiotensin II–evoked calcium flux is 
impaired significantly in vessels from PI3K  /  mice (*P   0.005, Student’s t 
test), whereas the effect of phenylephrine is comparable in both mouse 
strains (P   0.95). (C) Dose–response quantification of Ca2  flux induced 
by angiotensin II. PI3K  /  vessels show a significantly reduced response 
at all concentrations (n   5 for each genotype, P   0.001 as assessed by 
two-way ANOVA). (D) PI3K  /  vessels show reduced extracellular Ca2  
entry upon angiotensin II (0.1  M) stimulation. Vessels were treated with 
vehicle (basal) or angiotensin II before and after 10 min pretreatment with 
2  M thapsigargin (Thaps.) or 1  M nifedipine (Nif.). Vessels were exposed 
to vehicle (basal) or 0.1  M angiotensin II. Data represent the mean peak 
Ca2  mobilization from five independent experiments (*P   0.02 PI3K  /  
vs. wild-type; §P   0.01 PI3K  /  vs. wild-type as assessed by ANOVA). 
(E) Transfection of wild-type aortas with a DN-Akt reduces angiotensin II–
mediated [Ca2  ]i increase to the level detected in PI3K  /  samples. The 
empty plasmid (Ctrl) does not exert any effect.PI3K  VASCULAR EFFECTS | Vecchione et al. 1224
with flunarizine dihydrochloride (10  M) did not modify
the angiotensin II–dependent Ca2  response (unpublished
data). These findings demonstrate that PI3K  modulates
angiotensin II–dependent extracellular calcium entry via
L-type Ca2 channels.
L-type Ca2  channels can be regulated by the levels of
the second messenger, cAMP. Our previous results indicated
that in the heart, PI3K  helps to reduce cAMP concentration
independently of its kinase activity (10). PI3K  /  mice,
where PI3K  is absent, show increased cAMP in basal condi-
tions but no effect can be detected in PI3K KD/KD mice that
express a catalytically inactive PI3K . As increased cAMP
levels could influence L-type Ca2  channels of smooth mus-
cle negatively, cAMP concentration was determined in wild-
type and PI3K  /  aortas. In agreement with the finding that
in PI3K  /  and in PI3K KD/KD vessels angiotensin II–
dependent vasoconstriction is affected equally, measurements in
resting conditions and after stimulation with the  -adrenergic
agonist, isoproterenol (1  M), never revealed differences be-
tween wild-type and PI3K -deficient aortas (basal [cAMP]:
0.081   0.019 nmol/g and 0.062   0.022 nmol/g, respec-
tively; isoproterenol-induced [cAMP]: 0.391   0.140 nmol/g
and 0.280   0.174 nmol/g, respectively; n   6 for each
genotype). The finding that angiotensin II-dependent vaso-
constriction requires the kinase activity of PI3K  demon-
strates the involvement of signaling pathways that are linked
to PtdIns(3,4,5)P3 production. Because the enzymatic activity
of PI3K  is required for PKB/Akt phosphorylation, PKB/
Akt activation might mechanistically couple PI3K  to extra-
cellular Ca2  entry. To explore this hypothesis, PKB/Akt
was blocked by transfecting a DN-Akt in isolated vessels. A
reduction of angiotensin II–evoked vasoconstriction was de-
tected only in DN-Akt–transfected wild-type samples that
were leveled to the response of PI3K  /  vessels (24   6%
and 19   8% increase over basal in wild-type and PI3K  / 
samples, respectively; not significant; n   4 for each geno-
type). This result was supported fully by data on calcium fluc-
tuations which showed that DN-Akt expression blunted an-
giotensin II effects only in wild-type vessels (Fig. 7 E). In
contrast, expression of DN-Akt did not affect the PKB/Akt-
independent vascular response and calcium mobilization that
are induced by potassium (unpublished data). These data in-
dicate that angiotensin II acts on L-type Ca2  channels
through a PI3K /Akt pathway.
DISCUSSION
In this study, we demonstrated for the first time that PI3K 
is required for angiotensin II–evoked vasoconstriction and
that the inactivation of this enzyme protects from the hyper-
tensive response that is elicited by angiotensin II administra-
tion. We also provide evidence that PI3K  is a crucial medi-
ator of angiotensin II–dependent signaling in vascular smooth
muscle, where PI3K  controls vasoconstriction through ROS
production and PKB/Akt activation that lead to extracellular
Ca2  entry from L-type Ca2  channels.
It is well known that angiotensin II represents one of the
major mediators that is involved in the development of hy-
pertension. The protection from blood pressure increase af-
ter angiotensin II administration that was seen in PI3K  / 
mice has to be ascribed mainly to the vascular phenotype and
not to the previously reported enhancement of cardiac con-
tractility (8, 10), that should, in principle, increase cardiac
output and blood pressure. In agreement with this view, sev-
eral studies demonstrated that in the pathogenesis of angio-
tensin II–mediated hypertension, a critical role is played by
ROS production (21) as well as imbalanced homeostasis of
calcium (22, 23). Therefore, it is possible that the protection
from angiotensin II–induced hypertension that is observed in
the absence of PI3K  could be due to the beneficial reduc-
tion of oxidative stress and intracellular calcium concentra-
tion. However, PI3K -deficient vessels also were protected
from the chronic vascular remodeling that occurred as a con-
sequence of hypertensive vascular insult. Although a minor
involvement of inflammatory response, evoked particularly
by vascular ROS production, could not be excluded, our
data point to a crucial role of PI3K  in vascular smooth
muscle, rather than in the onset of vascular inflammation.
Although a previous report suggests that PI3K  is not
present in rat aortas (24), our finding of PI3K  expression in
aortic smooth muscle is in agreement with the established
notion of its existence in rat portal vein myocytes (14, 15).
Nevertheless, PI3K  was expressed at low levels and it is
possible that the different nature of the antibodies that were
used in the two studies might account for this discrepancy.
Our data further located p110  expression in cultured
ASMCs; however, analysis of angiotensin II stimulation re-
vealed that mutant cultured cells responded equally as well as
wild-type controls. In contrast, PI3K  /  intact vessels
showed a clearly impaired response to angiotensin II. As an
explanation for these divergent results, and in agreement
with previous studies (17) in ASMCs cultured in vitro, our
results suggest that the angiotensin II–dependent transactiva-
tion of the EGFR induces class IA PI3K-dependent activa-
tion and bypasses the requirement for PI3K  function. Our
data suggest that in intact aortas, the pathway that is depen-
dent on EGFR transactivation is less critical, and that, in
vivo, PI3K  is used preferentially for angiotensin II–medi-
ated PKB/Akt activation. Thus, our apparently contrasting
findings indicate that for the analysis of vascular signal trans-
duction events, in vivo experiments in genetically altered or-
ganisms are required; in vitro studies with primary ASMCs
might be limited by the adaptation of cells to culture condi-
tions. A similar situation was described in rat portal vein
myocytes that, when freshly isolated, express only p110 , - ,
and - , but start to express p110  after a few days of culture
(14). Because angiotensin II receptors can relay equally to
PI3K  and -  (14), the presence of PI3K  in cultured cells
might compensate for the absence of PI3K . The limited
amount of low-passage primary ASMCs that is obtainable
from mice and the lack of specific antibodies for immunohis-JEM VOL. 201, April 18, 2005 1225
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tochemistry prevented us from investigating whether PI3K 
is absent from ASMCs.
Nonetheless, our analysis of in vivo stimulated aortas
clearly indicated that multiple angiotensin II–mediated vas-
cular responses depend on PI3K . So far, several mecha-
nisms have been proposed to explain the activation of PI3K
and the subsequent phosphorylation of PKB/Akt that is in-
duced by angiotensin II. Although some studies include a
role for tyrosine kinase–activated class IA PI3Ks (1, 12, 17),
others reported that activation of Gq-coupled angiotensin II
receptors can mediate PKB/Akt phosphorylation (25). De-
spite these indications, we showed by genetic means that an-
giotensin II signals through PI3K  in intact aortas and that
this process is mediated by the activation of a Gi-coupled re-
ceptor. In general, signaling by the angiotensin II AT1 recep-
tors mainly is dependent on Gq-containing heterotrimeric G
proteins (26); however, other studies also point to an in-
volvement of Gi–coupled angiotensin II AT1 receptors, par-
ticularly in the angiotensin II–dependent inhibition of ade-
nylate cyclase (27). In addition, an involvement of Gi and
PI3K is crucial for the signal transduction events that lead to
Raf-1 activation in response to angiotensin II (28). In further
agreement with a role of Gi in the angiotensin II–mediated
signal transduction in smooth muscle cells, we and others
(29) found that treatment with PTX inhibits the angiotensin
II–dependent ROS generation. Our data indicate that the
Gi-dependent branch of angiotensin II signaling might have
considerable importance in the vascular responses that lead
to vasoconstriction and hypertension.
The finding that the addition of wortmannin, a PI3K in-
hibitor with no isoform selectivity, in wild-type tissues
blunted the angiotensin II–dependent vascular response to
the level that was observed in mutant arteries, indicated that
in intact vessels, PI3K  probably is the unique PI3K isoform
that is involved in the process. In vivo blockade of EGFR-
dependent signaling did not exert significant effects on an-
giotensin II–mediated PKB/Akt phosphorylation. Because
other agonists, such as phenylephrine or acetylcholine, ex-
erted identical effects in the two genotypes, the absence of
PI3K  did not induce a generalized impairment of vascular
function; this demonstrates a specific involvement of PI3K 
in the angiotensin II–dependent vascular contractile re-
sponse. In agreement with previous reports that suggested a
role of ROS in vasoconstriction (30), scavenging of angio-
tensin II–mediated ROS production reduced vasoconstric-
tion in wild-type preparations but was unable to exert a fur-
ther inhibitory effect in PI3K  /  samples. Consistently, we
found a marked reduction of ROS production in response
to angiotensin II in PI3K -null vessels. As an explanation for
this defective ROS generation, PI3K  seemed to be crucial
for angiotensin II activation of Rac, a key event that is re-
quired for NAD(P)H oxidase assembly and ROS generation
(17, 31). Our finding is in agreement with the PtdIns
(3,4,5)P3-dependent activation of GTP exchange factors
triggering Rac. The involvement of a similar mechanism in
the activation of NAD(P)H oxidase recently was outlined by
the cloning of P-Rex, a GTP exchange factor for Rac, that,
in neutrophils, mediates the respiratory burst response in a
GPCR- and PI3K-dependent way (32).
The mechanism by which free radicals increase vascular
tone has been attributed to a direct smooth muscle effect and
a reduced nitric oxide bioavailability (33). The finding of in-
creased nitration of tyrosines in wild-type, but not mutant,
vessels that were stimulated with angiotensin II, further sup-
ports this view and suggests that PI3K  contributes to the
angiotensin II–dependent depletion of vascular nitric oxide.
Although antioxidant agents reduced the angiotensin II–
dependent vasoconstriction in wild-type control samples, the
overall effect that was caused by the lack of PI3K  was sig-
nificantly stronger. This fact suggested that mechanisms
other than decreased ROS production could be triggered
concomitantly by PI3K  signaling and contribute to the im-
pact on angiotensin II vascular response. In addition to
through oxidative stress, angiotensin II can control vascular
tone by increasing intracellular calcium concentration in
smooth muscle cells (34). It is known that voltage-gated
L-type Ca2  channels represent the major pathway for calcium
entry and play an important role in excitation-contraction
coupling (35). Previous reports indicated that PI3K  may act
as a key mediator of angiotensin II–dependent voltage gated
L-type Ca2  channel activation in rat portal vein myocytes
(13, 14). In these cells, stimulation of angiotensin II recep-
tors frees the    dimer of the G13 protein and activates
PI3K , which, in turn, causes an increase in intracellular
Ca2  concentration. Furthermore, intracellular infusion of
an anti-PI3K  antibody causes reduced PtdIns(3,4,5)P3 gen-
eration, and the inhibition of angiotensin II elicited stimula-
tion of Ca2  current (15). In agreement with these data, our
results clearly showed that the angiotensin II–mediated ele-
vation of intracellular Ca2  concentration was defective in
PI3K  /  vessels. Our results with pharmacological inhibi-
tors further clarify that PI3K  is involved in the mobilization
of extracellular Ca2  through L-type channels, and does not
influence Ca2  release from intracellular stores. Thus, the
PI3K emerging signaling that was described to be involved
in the regulation of Ca2  release from intracellular stores in
cardiac cells through membrane anchoring of Tec and subse-
quent phospholipase C activation seems not to be recruited
by angiotensin II at the vascular level (36). Recently, PI3K 
was implicated, in this case in the heart, in a kinase-indepen-
dent activation of PDE3B, an enzyme that hydrolyzes
cAMP, a secondary messenger that controls L-type Ca2 
channels function (10). Despite this fact, cAMP concentra-
tion in aortas was not affected by the absence of PI3K ; in
addition, although cardiac contractility was different in mice
lacking PI3K  (PI3K  / ) or expressing a kinase-dead mu-
tant (PI3K KD/KD) (10), the angiotensin II–mediated vaso-
constriction was equally blunted in the two PI3K  /  and
PI3K KD/KD genotypes. This clearly excludes a cAMP-
related kinase-independent function of PI3K  in the angio-PI3K  VASCULAR EFFECTS | Vecchione et al. 1226
tensin II–mediated modulation of L-type Ca2  channel ac-
tivity at the vascular level. Conversely, in agreement with an
involvement of the catalytic activity of PI3K , PI3Ks were
found to enhance native voltage-dependent L-type Ca2 
currents through the activation of PKB/Akt, which causes
rapid plasma membrane relocalization of channel subunits
(37). Similarly, the expression of a constitutively active
PKB/Akt mutant in the murine heart leads to increased
L-type Ca2  channel activation and enhanced contractility
(38). ROS production can sustain PKB/Akt phosphoryla-
tion by the oxidative stress–dependent inactivation of the
PtdIns(3,4,5)P3 3-phosphatase, phosphatase with tensin ho-
mology (39). In this way, it could be hypothesized that the
concurrent production of PtdIns(3,4,5)P3 and ROS, induced
by angiotensin II, cooperate to keep PKB/Akt in its phos-
phorylated state, and consequently, increase L-type Ca2 
channel activity. Our results, which were obtained with
transfection of vessels with a dominant-negative form of
PKB/Akt blocked angiotensin II–evoked [Ca2 ]i increase,
clearly indicate that a PI3K /Akt signaling pathway crucially
regulates angiotensin II–mediated vascular contractility.
In light of these results, PI3K  represents a crucial intra-
cellular signaling molecule which drives multiple mechanisms
that are responsible for the angiotensin II–dependent vasculo-
toxic and hypertensive effects; thus, targeting this enzyme
with specific inhibitors could be exploited to expand the
therapeutic strategy that is aimed at treating hypertension.
MATERIALS AND METHODS
Mice. PI3K  /  (6) and PI3K KD/KD (10) mice were generated as previ-
ously described. For this study, 2-mo-old male 129sv inbred mice were
used. Mice were kept in standard cages under a 12-h light/dark cycle and
fed ad libitum and cared for according to guidelines of our institution. Ex-
periments conformed with institutional and national guidelines, and were
approved by the Italian Ministry of Health.
Evaluation of blood pressure in conscious mice. Radio-telemetric
analysis of blood pressure and echocardiography were assessed as described
(40). Angiotensin II (0.5 mg/kg/d in 0.9% NaCl), phenylephrine (0.15 mg/
kg/d in 0.2% ascorbic acid), or vehicle were infused for 21 d through os-
motic minipumps. Because blood pressure response in the first 3 d of
chronic infusion was masked by the stress response to surgical procedures,
acute blood pressure response to angiotensin II was evaluated by arterial
catheterization as described (41).
Evaluation of vascular reactivity. Vascular reactivity and structure were
assessed in mesenteric arteries as described previously (42). Increasing doses
of angiotensin II (10 9 to 10 6 M) were tested alone and in the presence of
the PI3K inhibitor, wortmannin (10 7 M, 30 min); the antioxidant agent,
tiron (10 3 M, 10 min); the AT1 antagonist, candesartan (10 6 M, 15 min);
or the AT2 antagonist, PD123319 (10 6 M, 15 min). Moreover, phenyl-
ephrine (10 9 to 10 5 M) and acetylcholine (10 9 to 10 5 M) vascular re-
sponses were tested in all vessels. For selected experiments, mechanical re-
moval of the endothelial layer was demonstrated by the absence of
acetylcholine-mediated vasorelaxation.
Isolation of ASMCs. ASMCs were isolated from male wild-type and
PI3K  /  mouse aortas using published procedures (43). All experiments
were performed using cells at the fourth/fifth passage. Cell lysates were pre-
pared from ASMCs at 80% confluence, starved for 24 h, and then stimulated
with the agonists. For RT-PCR analysis, total RNA was extracted using
RNAeasy columns (QIAGEN). Primers used were described previously (6).
In vivo aortic tissue stimulation. For in vivo angiotensin II stimula-
tion, mice were anesthetized with i.p. thiopental (50 mg/kg). Angiotensin
II was infused by i.p. injection. For PTX inhibition experiments, mice were
injected i.p. with PTX (150 mg/kg) 24 h before angiotensin II stimulation.
Effectiveness of the PTX treatment was assayed by the detection of full in-
hibition of muscarinic chronotropic response. At the end of angiotensin II
stimulation, thoracic aortas were removed and proteins were extracted.
Three distinct methods were used to evaluate oxidative stress: chemi-
luminescence with lucigenin (16), histochemistry with dihydroethidium,
and immunohistochemistry with anti-nitrotyrosine antibodies (44). Vascu-
lar Rac activity was measured using a commercially available kit (Upstate
Biotechnology).
Antibodies. Mouse monoclonal and rabbit polyclonal antibodies against
PI3K  were provided by R. Wetzker (University Hospital, Jena, Ger-
many). Immunohistochemistry was performed on paraffin sections of mouse
aorta by the ABC peroxidase method (Strepta ABComplex/HRP; Dako-
Cytomation). Antibodies against murine F4/80 antigen (CI:A3-1) and
CD18 (YTS 213.1) were from BMA Biomedicals. Rabbit polyclonal anti-
bodies against phospho-Ser473-Akt, Akt, and phospho-ERK1/2 were ob-
tained from New England BioLabs, Inc., antibodies against ERK1 (C16)
were obtained from Santa Cruz Biotechnology, Inc.
Evaluation of vascular angiotensin II–dependent Ca2  flux. Mesen-
teric arteries were placed at 37 C, in Krebs’ buffer (mM: 118.3 NaCl, 4.7
KCl, 2.5 CaCl2, 1.2 MgSO4   7 H2O, 1.2 KH2PO4, 25 NaHCO3, 5.6 glu-
cose), in a Mulvany micromyograph (Danish Myo Technology), and
stretched to the appropriate tension. The myograph was placed on the stage
of an inverted confocal microscope (Nikon). After the equilibration period,
the vascular responsiveness was tested with 80 mM KCl three times. To
view intracellular Ca2  oscillations, vessels were incubated for 2.5 h with
Fluo4-AM (60  M) plus 0.2% pluronic acid. Vessels were washed three
times with Krebs’ buffer and stimulated with angiotensin II (1  M) or
phenylephrine (1  M). Confocal images and [Ca2 ]i measurements were
acquired as described previously (45).
Mesenteric artery transfection. Vessels of PI3K  /  and wild-type
mice were transfected as described previously (46). Vessels were placed in a
Mulvany pressure system with DMEM/F12 medium, containing pCMV6
Vector (Origene Technologies) carrying a HA-tagged dominant negative
mutation of PKB/Akt (K179   M179) at the concentration of 3  g/ml. An
empty plasmid was used as a negative control. The vessels were perfused at
100 mm Hg of pressure for 1 h, and, subsequently, at 60 mm Hg for 5 h.
Transfection efficacy was tested by immunofluorescence with anti-HA
monoclonal antibodies (BabCo) in transfected and control sections of
mesenteric artery. The vascular contractility of transfected vessels, perfused at
constant flow, was assessed by pressure changes that were induced by angio-
tensin II (1  M) or KCl (80 mM).
Statistical analysis. Data are expressed as the mean   SEM. Comparisons
used were unpaired Student’s t test for differences between wild-type and
PI3K -deficient mice, or repeated measures two-way ANOVA followed by
Bonferroni post hoc test. p-value of  0.05 was assigned statistical significance.
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